Abstract
Venture capital (VC) plays a critical role in driving advancements in medical device innovations through its investment in early-stage companies. However, a concerning trend has emerged over the past decade: a decline in interest from VC funds toward investing in medical devices. Particularly alarming is the more than 50% decrease in investment in early-stage medical device development over the span of 2 decades. In the last 2 years, there has been a significant drop in small to mid-cap VC funds allocated toward the cardiovascular (CV) device space. These obstacles are exacerbated by several factors, including high interest rates, inflation, global economic slowdown, and ongoing international conflicts. These declining investments stifle innovation and jeopardize the timely development of life-saving technologies, highlighting the urgent need for increased funding support. This manuscript delves into the pivotal role of VC in CV device innovation and examines the challenges and concerns stemming from the downturn in VC financing within the CV device sector.